Current Report Filing (8-k)
June 03 2020 - 9:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 3, 2020
CELLECTAR
BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-36598
|
04-3321804
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
100 Campus Drive, Florham Park, New Jersey
07932
(Address of principal executive offices, and zip code)
(608) 441-8120
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, par value $0.00001
Warrant to purchase common stock, expiring
April 20, 2021
|
|
CLRB
CLRBZ
|
|
NASDAQ Capital Market
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 7.01
|
REGULATION FD DISCLOSURE
|
On June 3, 2020, Cellectar Biosciences, Inc., a Delaware corporation
(the “Company”) issued a press release announcing the pricing of an underwritten public offering for gross proceeds
of $20.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering is priced
at a public offering price of $1.15 per share of common stock and one-half of a Series H Warrant. Each whole Series H Warrant is
exercisable to purchase one share of our common stock at an exercise price of $1.21 per share, will be exercisable upon issuance
and will expire five years from the date of issuance. We are also offering to certain purchasers pre-funded warrants (the “Pre-Funded
Warrants”). The purchase price of each Pre-Funded Warrant and the accompanying one-half of a Series H Warrant will be equal
to the price at which a share of Common Stock and accompanying one-half of a Series H Warrant are sold to the public in this offering,
minus $0.00001, and the exercise price of each Pre-Funded Warrant will be $0.00001 per share. The Pre-Funded Warrants will be immediately
exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.
Oppenheimer & Co. Inc. acted as the sole book-running manager
in connection with the offering and Ladenburg Thalmann & Co. Inc. and Roth Capital Partners acted as co-lead managers. The
offering is expected to close on or about June 5, 2020, subject to the satisfaction of customary closing conditions.
The securities are being offered by the Company pursuant to
a Registration Statement on Form S-1 filed with the Commission under the Securities Act of 1933, as amended (the “Act”)
(File No. 333-238132), which was initially filed with the Securities and Exchange Commission on May 8, 2020, and an additional
registration statement filed pursuant to Rule 462(b) under the Act (File No. 333-238892).
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 3, 2020
|
CELLECTAR BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Dov Elefant
|
|
|
Name:
|
Dov Elefant
|
|
|
Title:
|
Chief Financial Officer
|
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Sep 2023 to Sep 2024